M
Manuel L. Penichet
Researcher at University of California, Los Angeles
Publications - 114
Citations - 5777
Manuel L. Penichet is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Antibody & Fusion protein. The author has an hindex of 38, co-authored 107 publications receiving 5092 citations. Previous affiliations of Manuel L. Penichet include University of California.
Papers
More filters
Journal ArticleDOI
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Tracy R. Daniels,Ezequiel Bernabeu,Ezequiel Bernabeu,Jose A. Rodriguez,Shabnum Patel,Maggie Kozman,Diego A. Chiappetta,Diego A. Chiappetta,Eggehard Holler,Julia Y. Ljubimova,Gustavo Helguera,Gustavo Helguera,Manuel L. Penichet +12 more
TL;DR: The present article discusses the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells and provides a summary of the vast types of anti-cancer drugs that have been delivered intocancer cells employing a variety of receptor binding molecules.
Journal ArticleDOI
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
TL;DR: Improvements in the basic physiology of the transferrin receptor including structure, function, and expression are summarized and the efficacy of targeting the TfR using cytotoxic antibodies that inhibit cell growth and/or induce apoptosis in targeted malignant cells is discussed.
Journal ArticleDOI
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.
TL;DR: The transferrin receptor, a cell membrane-associated glycoprotein involved in iron homeostasis and cell growth, has been explored as a target to deliver therapeutic agents into tumor cells by receptor-mediated endocytosis.
Journal ArticleDOI
Antibody-cytokine fusion proteins for the therapy of cancer.
TL;DR: In animals bearing tumors, antibody-cytokine fusion proteins are able to target the tumor and to elicit a significant anti-tumor response that in some cases results in a complete elimination of the tumor.
Journal ArticleDOI
AllergoOncology: the role of IgE-mediated allergy in cancer
Erika Jensen-Jarolim,Gernot Achatz,Michelle C. Turner,Sophia N. Karagiannis,Fanny Legrand,Monique Capron,Manuel L. Penichet,Jose A. Rodriguez,Antonio G. Siccardi,Luca Vangelista,Angelika B. Riemer,Hannah J. Gould +11 more
TL;DR: It could be demonstrated that IgE antibodies specific to overexpressed tumor antigens have been superior to any other immunoglobulin class with respect to antibody‐dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) reactions.